Our lead program candidate, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein designed to provide potential long-acting attack prevention for HAE. The prefix “nav-” represents Astria’s commitment to navigating the development of navenibart with patients as our guiding stars. The infix “-eni-” represents “enzyme inhibitor” and the suffix “-bart” represents “monoclonal antibody.”
Learn how navenibart aims to prevent attacks in HAE by exploring the mechanism of action here:
Preclinical results to date show navenibart’s differentiated profile, with high potency and a long plasma half-life, predicting that navenibart could be an effective preventative therapy with the potential for dosing once every 3 and 6 months.
We’ve heard from the HAE community the desire to normalize their lives, living without limitations from their symptoms and treatments. Our goal is to reduce the disease and treatment burden for people living with HAE, whose current options for preventative therapies require frequent administration (daily or up to every 4 weeks). We believe we can do better with navenibart.
Based on the near-term HAE treatment landscape, our Phase 1a data and Phase 1b/2 initial proof-of-concept results support our vision that navenibart can become the new standard of care for HAE attack prevention with dosing every 3 and 6 months.
